ARS Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ARS Pharmaceuticals, Inc. (SPRY) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $20.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $10.52M, a 17.86% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $10.31M, a 147.48% increase year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$9.06M, a 218.27% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $10.96M, a 152.68% increase year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $18.88M, a 15.04% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $16.41M.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$2.78M.
- ARS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$10.29M, a 1155.95% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $20.84M 10-Q · filed 2026-08-13 | $11.78M derived: sum of 3 quarters · filed 2026-08-13 | $22.74M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $10.31M 10-Q · filed 2026-05-15 | $1.25M derived: sum of 2 quarters · filed 2026-05-15 | $12.21M derived: sum of 3 quarters · filed 2026-05-15 | $25.03M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$9.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.90M derived: sum of 2 quarters · filed 2026-03-09 | $14.71M derived: sum of 3 quarters · filed 2026-08-13 | $18.88M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $10.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $23.78M derived: sum of 2 quarters · filed 2026-08-13 | $27.95M 10-Q · filed 2025-11-10 | $35.61M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $12.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $16.98M 10-Q · filed 2026-08-13 | $24.64M derived: sum of 3 quarters · filed 2026-08-13 | $28.98M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $4.17M 10-Q · filed 2026-05-15 | $11.83M derived: sum of 2 quarters · filed 2026-05-15 | $16.17M derived: sum of 3 quarters · filed 2026-05-15 | $19.24M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.00M derived: sum of 2 quarters · filed 2026-03-09 | $15.07M derived: sum of 3 quarters · filed 2026-03-09 | $16.41M 10-K · filed 2026-03-09 | $16.43M 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $4.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.41M derived: sum of 2 quarters · filed 2025-11-10 | $8.75M 10-Q · filed 2025-11-10 | -$132.00K derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.41M 10-Q · filed 2025-08-13 | -$4.47M derived: sum of 3 quarters · filed 2025-08-13 | -$3.35M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-14 | -$7.54M derived: sum of 2 quarters · filed 2025-05-14 | -$6.41M derived: sum of 3 quarters · filed 2025-05-14 | -$6.19M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$7.76M derived: sum of 2 quarters · filed 2025-03-20 | -$7.53M derived: sum of 3 quarters · filed 2025-03-20 | -$2.78M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.35M derived: sum of 2 quarters · filed 2024-11-13 | $6.10M 10-Q · filed 2024-11-13 | -$5.32M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.98M 10-Q · filed 2024-08-06 | -$6.44M derived: sum of 3 quarters · filed 2024-08-06 | -$5.58M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $4.76M 10-Q · filed 2024-05-09 | -$6.67M derived: sum of 2 quarters · filed 2024-05-09 | -$5.81M derived: sum of 3 quarters · filed 2024-05-09 | -$6.08M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$11.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$10.56M derived: sum of 2 quarters · filed 2024-03-21 | -$10.83M derived: sum of 3 quarters · filed 2024-03-21 | -$10.29M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $859.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $592.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.14M 10-Q · filed 2023-11-09 | -$10.01M 10-Q · filed 2022-11-02 | -$4.31M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$267.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $279.00K 10-Q · filed 2023-08-10 | -$3.56M 10-Q · filed 2022-08-11 | -$5.17M derived: sum of 3 quarters · filed 2023-08-10 | -$5.54M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $546.00K 10-Q · filed 2023-05-15 | -$186.00K 10-Q · filed 2022-05-12 | -$4.90M derived: sum of 2 quarters · filed 2023-05-15 | -$5.27M derived: sum of 3 quarters · filed 2023-05-15 | -$688.00K derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$5.82M derived: sum of 2 quarters · filed 2023-03-23 | -$1.23M derived: sum of 3 quarters · filed 2023-03-23 | $974.00K 10-K · filed 2023-03-23 | $6.03M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | -$367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.21M derived: sum of 2 quarters · filed 2022-11-02 | $6.42M 10-Q · filed 2022-11-02 | $9.13M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $4.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $6.79M 10-Q · filed 2022-08-11 | $9.49M derived: sum of 3 quarters · filed 2022-08-11 | $10.22M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $2.21M 10-Q · filed 2022-05-12 | $4.91M derived: sum of 2 quarters · filed 2022-05-12 | $5.64M derived: sum of 3 quarters · filed 2022-05-12 | $6.70M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.43M derived: sum of 2 quarters · filed 2022-03-31 | $4.49M derived: sum of 3 quarters · filed 2022-03-31 | $1.79M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $725.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.78M derived: sum of 2 quarters · filed 2021-11-10 | -$914.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.64M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$2.70M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |